The estimated Net Worth of Christopher T Phd Walsh is at least $698 mil dollars as of 7 November 2012. Christopher Walsh owns over 85,000 units of Cortexyme Inc stock worth over $698,151 and over the last 20 years Christopher sold CRTX stock worth over $0.
Christopher has made over 2 trades of the Cortexyme Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Christopher exercised 85,000 units of CRTX stock worth $172,550 on 7 November 2012.
The largest trade Christopher's ever made was exercising 85,000 units of Cortexyme Inc stock on 7 November 2012 worth over $172,550. On average, Christopher trades about 3,138 units every 10 days since 2004. As of 7 November 2012 Christopher still owns at least 358,026 units of Cortexyme Inc stock.
You can see the complete history of Christopher Walsh stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O CRITICAL THERAPEUTICS, INC., 60 WESTVIEW STREET, LEXINGTON, MA, 02421.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi y Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: